Welcome to the REVLIMID REMS^® program

REVLIMID^® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Important information about REVLIMID and the REVLIMID Risk Evaluation
and Mitigation Strategy (REMS) program

• REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy

• To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID REMS^®"

• Only prescribers and pharmacies certified by the REVLIMID REMS^® program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS^® program

The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:

1. To prevent the risk of embryo-fetal exposure to REVLIMID

2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID